State of Alaska Department of Revenue Has $301,000 Stock Position in LivaNova PLC (NASDAQ:LIVN)

State of Alaska Department of Revenue reduced its position in shares of LivaNova PLC (NASDAQ:LIVN) by 9.9% during the fourth quarter, according to the company in its most recent 13F filing with the SEC. The firm owned 5,821 shares of the company’s stock after selling 640 shares during the quarter. State of Alaska Department of Revenue’s holdings in LivaNova were worth $301,000 at the end of the most recent quarter.

A number of other institutional investors have also added to or reduced their stakes in the company. Bank of Montreal Can increased its holdings in LivaNova by 213.3% during the 1st quarter. Bank of Montreal Can now owns 35,725 shares of the company’s stock worth $2,912,000 after purchasing an additional 24,324 shares in the last quarter. Panagora Asset Management Inc. bought a new stake in LivaNova during the 1st quarter worth approximately $256,000. Rhumbline Advisers increased its holdings in LivaNova by 2.1% during the 1st quarter. Rhumbline Advisers now owns 147,621 shares of the company’s stock worth $12,080,000 after purchasing an additional 2,980 shares in the last quarter. Commonwealth of Pennsylvania Public School Empls Retrmt SYS increased its holdings in LivaNova by 10.5% during the 1st quarter. Commonwealth of Pennsylvania Public School Empls Retrmt SYS now owns 19,506 shares of the company’s stock worth $1,596,000 after purchasing an additional 1,859 shares in the last quarter. Finally, Yousif Capital Management LLC increased its holdings in LivaNova by 2.4% during the 1st quarter. Yousif Capital Management LLC now owns 28,279 shares of the company’s stock worth $2,314,000 after purchasing an additional 661 shares in the last quarter. 97.64% of the stock is owned by institutional investors and hedge funds.

LivaNova Trading Down 2.0 %

NASDAQ:LIVN opened at $52.99 on Friday. The company has a market cap of $2.86 billion, a P/E ratio of 165.60 and a beta of 0.89. The stock’s fifty day moving average price is $53.30 and its two-hundred day moving average price is $50.54. LivaNova PLC has a 1 year low of $42.44 and a 1 year high of $59.86. The company has a debt-to-equity ratio of 0.44, a current ratio of 2.95 and a quick ratio of 2.51.

LivaNova (NASDAQ:LIVN) last issued its quarterly earnings data on Wednesday, February 21st. The company reported $0.87 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.77 by $0.10. LivaNova had a return on equity of 12.23% and a net margin of 1.53%. The company had revenue of $310.10 million for the quarter, compared to the consensus estimate of $287.65 million. During the same quarter last year, the business posted $0.81 earnings per share. The firm’s revenue was up 12.8% compared to the same quarter last year. As a group, analysts expect that LivaNova PLC will post 3.01 EPS for the current year.

Wall Street Analyst Weigh In

A number of analysts have commented on the company. Needham & Company LLC reissued a “buy” rating and set a $72.00 price objective on shares of LivaNova in a report on Wednesday, March 20th. Mizuho reaffirmed a “buy” rating and issued a $75.00 target price on shares of LivaNova in a report on Wednesday, March 27th. Barclays upped their target price on LivaNova from $57.00 to $61.00 and gave the company an “equal weight” rating in a report on Monday, February 26th. Finally, Robert W. Baird increased their price objective on LivaNova from $56.00 to $62.00 and gave the company a “neutral” rating in a report on Thursday, February 22nd. Three investment analysts have rated the stock with a hold rating and three have given a buy rating to the stock. According to MarketBeat.com, LivaNova has an average rating of “Moderate Buy” and a consensus price target of $64.40.

LivaNova Company Profile

LivaNova PLC, a medical device company, designs, develops, manufactures, and sells therapeutic solutions worldwide. The company operates through Cardiopulmonary, Neuromodulation, and Advanced Circulatory Support segments. The Cardiopulmonary segment develops, produces, and sells cardiopulmonary products, including oxygenators, heart-lung machines, autotransfusion systems, perfusion tubing systems, cannulae, connect, and other related products.